Quetiapine augmentation in treatment-resistant depression: a naturalistic study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Treatment-resistant depression (TRD) is a common clinical problem, often complicated with suicidal ideations and greater lifetime functional impairment, and represents a considerable challenge to management and treatment.
The aim of a prospective, open-label, noncomparative, flexible-dosed 20-week study was to evaluate the effects of quetiapine, as an add-on therapy, in patients with TRD who were refractory to previous treatments.
Eighteen patients with major depressive disorder (DSM-IV criteria) were treated for 20 weeks with quetiapine (mean dose 315±109 mg/day). Patients were evaluated at baseline, weekly from 1 to 9 weeks, and then after 12, 16, and 20 weeks of treatment, using Hamilton rating scale for depression–17 items (HAMD) scale.
Fourteen patients with TRD completed the 20-week open trial with quetiapine. The augmentation with quetiapine significantly reduced total scores and scores listed in the anxiety subscale on the HAMD, and these effects were observed after the fourth week of treatment, while the depressed mood scores were significantly reduced after the fifth week of treatment. Quetiapine add-on treatment significantly decreased the scores listed in the insomnia subscale on the HAMD subscale after the second week of treatment.
Our preliminary data indicate that quetiapine add-on therapy appears to have beneficial effects in the treatment of patients with TRD.
- Adityanjee, Schulz SC (2002) Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 63:32–38
- Adson DE, Kushner MG, Kathryn ME, Eiben MA, Schulz (2004) Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 19:121–126 CrossRef
- American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC
- Annath J (1998) Treatment-resistant depression. Psychother Psychosom 67:61–70 CrossRef
- Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, Rüther E (2004) Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 174:421–429
- Cohrs S, Röher C, Jordan W, Meier A, Huether G, Wuttke W, Rüther E, Rodenbeck A (2006) The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 185:11–18 CrossRef
- Devarajan S, Ali J, Dursun SM (2006) Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms. Psychopharmacology 185:402–403. DOI 10.1007/s00213-006-0314-6 CrossRef
- DeVane CL, Nemeroff CB (2001) Clinical pharmacokinetics of quetiapine an atypical antipsychotic. Clin Pharmacokinet 40:509–522 CrossRef
- Dodd S, Horgan D, Malhi GS, Berk M (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89:1–11 CrossRef
- Hamilton M (1960) A rating scale for depression. J Neurosurg Psychiatry 23:56–62 CrossRef
- Kennedy SH, Lam RW (2003) Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 5(Suppl 2):36–47 CrossRef
- Malhi GS, Parker GB, Crawford J, Wilhelm K, Mitchell PB (2005) Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand 112:302–309 CrossRef
- Nemeroff CB (2005) Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 66(Suppl 8):13–21
- Nemeroff CB, Kinkead B, Goldstein J (2002) Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63(Suppl 13):5–11
- Pathak S, Johns ES, Kowatch RA (2005) Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacology 15:696–702 CrossRef
- Robert S, Hamner MB, Kose S, Ulmer HG, Deitsch SE, Lorberbaum JP (2005) Quetiapine improves sleep disturbances in combat veterans with PTSD (letter). J Clin Psychopharmacol 25:387–388 CrossRef
- Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ (2005) Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 66:450–454 CrossRef
- Sharpley AL, Bhagwagar Z, Hafizi S, Whale WR, Gijsman HJ, Cowen PJ (2003) Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry 64:192–196 CrossRef
- Tandon R, Jibson MD (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28:9–26 CrossRef
- Quetiapine augmentation in treatment-resistant depression: a naturalistic study
Volume 187, Issue 4 , pp 511-514
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Treatment-resistant depression
- Add-on therapy
- Industry Sectors
- Author Affiliations
- 1. Department of Psychiatry, Clinical Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia
- 2. Division of Molecular Medicine, Rudjer Boskovic Institute, P.O. Box 180, 10002, Zagreb, Croatia